Pharmaceutical Glossary

The total drug exposure over time, calculated as the integral of the plasma concentration-time curve. AUC reflects overall systemic drug exposure and is the primary …

The fraction of an administered drug dose that reaches systemic circulation in unchanged form. Intravenous drugs have 100% bioavailability by definition, while oral drugs are …

The volume of plasma from which a drug is completely removed per unit time, reflecting the body's efficiency at eliminating the drug. Clearance is primarily …

The phenomenon where an orally administered drug is significantly metabolized by the liver before reaching systemic circulation. This reduces the amount of active drug available …

The time required for the plasma concentration of a drug to decrease by 50%. Half-life determines how often a medication needs to be dosed — …

The highest concentration of a drug measured in the blood after a dose is administered. Cmax is important because it determines whether a drug reaches …

The reversible binding of drugs to plasma proteins (primarily albumin). Only the unbound (free) fraction of a drug is pharmacologically active. Highly protein-bound drugs can …

The condition where the rate of drug administration equals the rate of drug elimination, resulting in a stable average plasma concentration. Steady state is typically …

The time after drug administration when the peak plasma concentration (Cmax) is observed. Tmax indicates how quickly a drug begins working at maximum effect.

A theoretical volume that relates the total amount of drug in the body to its plasma concentration. A large Vd indicates the drug distributes extensively …

A drug that binds to a receptor and activates it, producing a biological response that mimics the body's natural signaling molecules. Full agonists produce the …

A drug that binds to a receptor but does not activate it, instead blocking the receptor and preventing agonists from producing their effect. Competitive antagonists …

A graphical representation of the relationship between drug dose and the magnitude of its effect. The curve typically has a sigmoidal (S-shaped) form and is …

The median effective dose — the dose of a drug that produces the desired therapeutic effect in 50% of the population. ED50 is a key …

The maximum therapeutic effect a drug can produce, regardless of the dose given. A drug with higher efficacy can achieve a greater maximum response than …

The median lethal dose — the dose of a drug that causes death in 50% of test animals. LD50 is used in preclinical safety testing …

The amount of drug needed to produce a given effect. A more potent drug achieves the same effect at a lower dose. Potency is different …

The ability of a drug to preferentially bind to and affect one specific receptor type over others. Higher selectivity generally means fewer side effects because …

The ratio between the toxic dose and the therapeutic dose of a drug (TD50/ED50). A narrow therapeutic index means there is a small margin between …

A decrease in a drug's effect over time with repeated administration, requiring higher doses to achieve the same response. Tolerance develops through receptor downregulation, enzyme …

An unintended and harmful response to a medication at normal therapeutic doses. ADRs range from mild (nausea, headache) to severe (anaphylaxis, organ damage). Type A …

The strongest safety warning issued by the FDA, appearing in a black-bordered box at the top of a drug's prescribing information. Black box warnings alert …

The classification system used by the Drug Enforcement Administration to categorize controlled substances based on their accepted medical use and potential for abuse. Schedule I …

The removal or correction of a marketed drug product that the FDA considers to be in violation of laws or presents a risk to health. …

A classification system (Categories A, B, C, D, X) that was used to indicate the risk of drug use during pregnancy. In 2015, the FDA …

The formal request submitted to the FDA by a pharmaceutical company to gain approval to market a new drug in the United States. An NDA …

The use of a drug for a purpose, population, or dosage not included in its FDA-approved labeling. Off-label prescribing is legal and common — an …

A drug developed to treat a rare disease or condition affecting fewer than 200,000 people in the United States. The Orphan Drug Act provides manufacturers …

Medications that can be purchased without a prescription, deemed safe for consumer use when following the label directions. The FDA determines OTC status based on …

A medication that legally requires a healthcare provider's prescription before dispensing. Prescription-only status is assigned when a drug's risks require professional supervision — due to …

A polymer coating applied to tablets or capsules that resists dissolution in the acidic stomach environment but dissolves in the alkaline intestine. Enteric coatings protect …

An inactive ingredient in a drug formulation that serves a purpose other than the therapeutic effect — such as binding, filling, flavoring, coloring, or preserving …

A drug formulation designed to release the active ingredient gradually over an extended period, allowing less frequent dosing. Extended-release tablets should not be crushed or …

A drug formulation that releases the entire dose immediately upon administration, allowing rapid absorption and quick onset of action. IR formulations typically require more frequent …

A route of drug administration where medication is injected into muscle tissue, providing relatively rapid absorption through the muscle's blood supply. IM injections can deliver …

A route of drug administration where medication is delivered directly into a vein, providing immediate and complete bioavailability. IV administration allows precise dosing control and …

A pharmacologically inactive compound that is converted to an active drug inside the body through metabolic processes. Prodrugs are designed to improve absorption, reduce side …

A route of drug administration where medication is injected into the layer of fat and connective tissue just beneath the skin. Absorption is slower than …

A route of drug administration where the medication is placed under the tongue, allowing absorption through the highly vascular sublingual mucosa directly into the bloodstream. …

A medicated adhesive patch placed on the skin that delivers a controlled dose of drug through the skin into the bloodstream over an extended period. …

An interaction where one drug reduces or blocks the effect of another drug. This can occur through pharmacodynamic antagonism (opposing receptor effects) or pharmacokinetic antagonism …

A superfamily of liver enzymes responsible for metabolizing approximately 75% of all drugs. Key isoforms include CYP3A4 (metabolizes ~50% of drugs), CYP2D6, CYP2C9, and CYP1A2. …

An alteration in a drug's absorption, metabolism, or effect caused by food or specific dietary components. Some interactions reduce drug effectiveness, while others increase drug …

The process by which a drug increases the production of metabolizing enzymes (particularly CYP450), leading to faster breakdown of itself or other drugs. This can …

The process by which a drug decreases the activity of metabolizing enzymes, leading to slower breakdown and increased blood levels of co-administered drugs. Unlike induction, …

The interaction between grapefruit (juice or fruit) and certain medications, caused by furanocoumarins in grapefruit that irreversibly inhibit CYP3A4 enzymes in the intestinal wall. This …

The concurrent use of multiple medications by a patient, typically defined as five or more drugs. Polypharmacy increases the risk of drug interactions, adverse effects, …

A delay in the electrical repolarization of the heart's ventricles, visible on an ECG as a lengthened QT interval. Drug-induced QT prolongation increases the risk …

A potentially life-threatening condition caused by excessive serotonergic activity, usually from combining two or more drugs that increase serotonin levels. Symptoms include agitation, confusion, rapid …

An interaction where the combined effect of two drugs is greater than the sum of their individual effects. Synergism can be therapeutically beneficial (combining antibiotics) …

The sequential stages of testing a new drug in humans. Phase I tests safety in 20-100 healthy volunteers. Phase II tests efficacy in 100-300 patients. …

A clinical trial design where neither the participants nor the researchers know who is receiving the active drug versus placebo. Double-blinding prevents both patient expectations …

The demonstration that a generic drug delivers the same amount of active ingredient to the bloodstream at the same rate as the brand-name product. The …

A statistical analysis method in clinical trials that includes all randomized participants in their originally assigned groups, regardless of whether they completed the treatment or …

The number of patients who need to be treated with a drug for one additional patient to experience a specific adverse effect compared to a …

The number of patients who need to be treated with a drug for one additional patient to benefit compared to a control treatment. A lower …

The science and activities relating to the detection, assessment, understanding, and prevention of adverse drug effects. Pharmacovigilance continues throughout a drug's entire market life and …

A measurable improvement in a patient's condition that occurs after receiving an inert treatment (placebo) with no active therapeutic ingredient. The placebo effect is driven …

A clinical study design where participants are randomly assigned to either the treatment group or a control group (placebo or standard treatment). Randomization minimizes selection …

Dispensing a different drug from the one prescribed, but within the same therapeutic class, when the prescribed drug is unavailable or for cost reasons. Unlike …

A planned, temporary discontinuation of a medication, typically to reduce long-term side effects, restore drug sensitivity, or assess whether the medication is still needed. Drug …

Modification of drug dose for patients with liver disease, as the liver is the primary site of drug metabolism. Unlike renal adjustment, hepatic adjustment is …

An initial higher dose of medication given to rapidly achieve therapeutic blood levels before transitioning to a lower maintenance dose. Loading doses are used for …

The regular dose of medication given at fixed intervals to maintain the drug at therapeutic steady-state levels. The maintenance dose replaces the amount of drug …

The extent to which a patient takes medications as prescribed — at the correct dose, frequency, and duration. Poor adherence affects approximately 50% of patients …

From the Latin 'pro re nata' meaning 'as the situation demands' — medications taken only when needed rather than on a fixed schedule. PRN dosing …

Modification of drug dose or dosing interval for patients with impaired kidney function. Since many drugs are eliminated by the kidneys, reduced kidney function (measured …

The gradual reduction of a drug dose over time to prevent withdrawal symptoms or rebound effects. Abrupt discontinuation of certain drugs (corticosteroids, benzodiazepines, antidepressants, opioids) …

The measurement of drug concentrations in blood at specific times to optimize individual dosing. TDM is essential for drugs with narrow therapeutic indices, significant pharmacokinetic …

The gradual adjustment of a drug dose, typically starting low and increasing incrementally until the desired therapeutic effect is achieved with acceptable side effects. The …

The component of a drug product that produces the intended therapeutic effect. The active pharmaceutical ingredient (API) is what the drug does — everything else …

The Anatomical Therapeutic Chemical classification system maintained by the World Health Organization, which organizes drugs into groups at five levels based on the organ system …

A medication derived from living organisms or their components, including proteins, antibodies, vaccines, and gene therapies. Biologics are larger and more complex than traditional small-molecule …

A biologic drug that is highly similar to an already approved reference biologic product, with no clinically meaningful differences in safety, purity, or potency. Unlike …

A drug marketed under a proprietary, trademarked name by the company that originally developed it. Brand-name drugs are protected by patents (typically 20 years from …

A single pharmaceutical product containing two or more active ingredients, designed to improve efficacy, reduce side effects, or simplify dosing. Fixed-dose combinations are increasingly used …

A group of medications that share a similar chemical structure, mechanism of action, or therapeutic use. Drugs within the same class often have similar effects, …

A medication that contains the same active ingredient, dosage form, strength, and route of administration as a brand-name drug, and has been demonstrated to be …

Any component of a drug product other than the active ingredient. Inactive ingredients include binders (hold tablets together), fillers (bulk up the tablet), disintegrants (help …

A conventional drug with a low molecular weight (typically <900 daltons) that is produced by chemical synthesis. Small molecules can usually be taken orally, easily …